Rebel Medicine

Rebel Medicine is a clinical-stage biotechnology company developing innovative drug delivery systems and non-opioid pain therapeutics. Their lead asset, Alevatrix™, is a novel, long-acting formulation of bupivacaine designed to reduce or eliminate the need for opioids after surgery. They aim to bring opioid-sparing pain therapies to patients faster.

Funding Round: Series A

Funding Amount: $6M

Date: 12-Jun-2025

Investors: Crocker Ventures, Central Texas Angel Network (CTAN), Prosperity Solutions Capital, Utah Innovation Fund, SK Hart, the Joan & Tim Fenton Fund, Cantina Angels, a syndicate of experienced life-science angel investors

Markets: Biotechnology, Pharmaceuticals, Drug Delivery, HealthTech, Life Sciences

HQ: Salt Lake City, Utah, United States

Founded: 2020

Website: https://www.rebelmedicine.com

LinkedIn: https://www.linkedin.com/company/rebelmedicineinc/

Twitter: https://twitter.com/rebelmedinc

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/rebel-medicine

Pitchbook: https://pitchbook.com/profiles/company/463080-43